See the DrugPatentWatch profile for tigecycline

Based on the information available, there is a potential link between the overuse of the antibiotic tigecycline and decreased survival odds in severe infections. A study published in the journal Chest in 2016 found that tigecycline use was associated with increased 30-day mortality in patients with severe infections, such as hospital-acquired pneumonia and bloodstream infections [1].

The authors of the study suggest that this may be due to the drug's weak activity against certain bacteria, as well as its lack of concentration in tissues where infections often occur. Additionally, tigecycline has been noted for its high volume of distribution and low serum concentrations, which may contribute to the development of antibiotic resistance [1].

It is important to note that tigecycline, which is manufactured by Pfizer and came off-patent in 2018 [2], should be used judiciously and as a last resort for severe infections caused by drug-resistant bacteria. The Infectious Diseases Society of America (IDSA) recommends that tigecycline should not be used as a first-line therapy for hospital-acquired pneumonia or ventilator-associated pneumonia [3].

In summary, based on the available information, there is a potential link between tigecycline overuse and decreased survival odds in severe infections. It is crucial to use this antibiotic judiciously and as a last resort for severe infections caused by drug-resistant bacteria.

Sources:
[1] Chest. 2016 Aug;150(2):315-24. doi: 10.1016/j.chest.2016.02.012. Epub 2016 Mar 11. PMID: 27163353.
[2] <https://www.drugpatentwatch.com/drugs/tigecycline>
[3] <https://www.idsociety.org/globalassets/idsa/infectious-diseases-practice/id-practice-guidelines/hospital-acquired-pneumonia-2016.pdf>